Varicella vaccine:
The all the cost-effectiveness studies I have seen to date have been performed assuming a single dose would be required. It is now know at least two are required, and the possibility of having to vaccinate a load more people against HZ for the next 20-30 years is looking more likely. IIRC, the HZ vaccine is an even more expensive than the Varicella vaccine.
It seems bizarre to me (as an engineer who has worked on high-volume cost-sensitive projects worth hundreds of millions, where adding less than 10% to the estimated manufacturing cost is questioned), that a 200-400% increase is being ignored in the US, especially when one of the primary reasons given for the introduction of the vaccine was that is was cost-effective.
Since this is a continuation of a previous thread discussion, permit me to remind you of what you failed to include in your cost/benefit assessment then and now. You neglected to include the cost of lost work time, the cost of hospitalizations, the costs of doctor's visits, the cost of additional morbidity and mortality that occurs from being in any hospital that is not recorded as a direct cost of varicella disease, the outbreaks of invasive group A strep (aka flesh eating infections) in children with acute chicken pox, the cost of long term health care for those suffering permanent lung damage from varicella and the tragedy of the loss of a loved one, especially a child or young adult who may be the parent of a young child.
As I reviewed several abstracts where the authors concluded it best regarding cost/benefit to vaccinate teens and older for varicella, I noticed two recurring themes.
One, they underestimate the actual cost of varicella morbidity and mortality due to what was included in the impact of varicella.
And two, more importantly, the cost benefit impact was to the third party payer's budget whether that be national health insurance or a private insurance company. If a parent loses work time with an ill child, that isn't a concern of the insurer. If a parent loses their child, that doesn't count as a cost to the insurer.
NACI [Canadian ACIP equivalent] UPDATE TO STATEMENT ON VARICELLA VACCINE
Varicella is often considered to be a fairly benign disease among otherwise healthy children < 12 years of age. However, not only does this group account for approximately 90% of all varicella cases, but also for 80% to 85% of varicella-associated physician visits, 85% to 90% of hospitalizations, nearly 50% of fatal cases and the majority of annual costs, most of which are related to productivity losses by caregivers.
Complications include secondary bacterial skin and soft tissue infections, otitis media, bacteremia, osteomyelitis, septic arthritis, endocarditis, necrotizing fasciitis, toxic shock-like syndrome, mild hepatitis and thrombocytopenia. Studies in Canada and the United States (U.S.) have estimated that varicella increases the risk of severe invasive Group A beta hemolytic streptococcus (GABHS) infection among previously healthy children, by 40- to 60-fold(4,11). Rare neurologic complications include cerebellar ataxia and encephalitis. Complications are more likely to occur when chickenpox is acquired in adolescence or adulthood, with higher rates of pneumonia, encephalitis and death. Case fatality rates among adults are 10 to 30 times higher than in children. In the U.S., adults account for only 5% of cases, but constitute 55% of an approximate 100 chickenpox deaths each year. In Canada, 70% of the 53 reported chickenpox deaths from 1987 to 1996 were among those > 15 years of age.
The medical and societal costs of varicella in Canada were estimated, from a multicentre study, as a total yearly cost of $122.4 million dollars, or $353.00 per individual case(5,6). Eighty-one percent of the costs went towards personal expenses and productivity costs, 9% towards the cost of ambulatory medical care and 10% towards hospital-based medical care.
Here the costs measured included a broad range of consequences including the costs of all the uncomplicated childhood cases. Those costs are completely left out of any number of analyses which only looked at the cost of severe disease as if routine cases had no financial impact.
Compare that to this discussion,
The cost-effectiveness of varicella vaccination in Canada.
A deterministic realistic age-structured model was used to predict the impact of vaccination on the incidence of varicella and zoster. Unit costs, estimated from literature, were applied to the predicted health outcomes. Various vaccination programs were investigated and a sensitivity analysis was performed. Assuming no impact of vaccination on zoster, varicella vaccination is estimated to cost 45,000 dollars, 51,000 dollars and 18,000 dollars per life-year gained from the health payer's perspective for infant, infant with catch-up campaign, and preteen programs, respectively. From the societal perspective, mass infant varicella vaccination was estimated to be highly cost saving in Canada. Importantly, infant varicella vaccination could result in a short- to medium-term increase of zoster incidence and thus cause vaccination to be highly cost-ineffective (118,000 dollars per life-year gained) under the health payer's perspective. From a health payer's perspective the preteen vaccination is the only strategy that is deemed cost-effective. The cost-effectiveness of infant vaccination rests heavily on the unknown relationship between varicella and zoster.
Decline in Mortality Due to Varicella after Implementation of Varicella Vaccination in the United States
Results The rate of death due to varicella fluctuated from 1990 through 1998 and then declined sharply. For the interval from 1990 through 1994, the average number of varicella-related deaths was 145 per year (varicella was listed as the underlying cause in 105 deaths and as a contributing cause in 40); it then declined to 66 per year during 1999 through 2001. For deaths for which varicella was listed as the underlying cause, age-adjusted mortality rates dropped by 66 percent, from an average of 0.41 death per 1 million population during 1990 through 1994 to 0.14 during 1999 through 2001 (P<0.001). This decline was observed in all age groups under 50 years, with the greatest reduction (92 percent) among children 1 to 4 years of age. In addition, by the period from 1999 through 2001, the average rates of mortality due to varicella among all racial and ethnic groups were below 0.15 per 1 million population, as compared with rates ranging from 0.37 per 1 million for whites to 0.66 per 1 million for other races in the period from 1990 through 1994.
Conclusions The program of universal childhood vaccination against varicella in the United States has resulted in a sharp decline in the rate of death due to varicella....
...Discussion
An average of 145 varicella-related deaths per year occurred in the United States from 1990 through 1994, a higher number than was previously recognized, owing to the fact that reports had been based solely on deaths for which varicella was listed as the underlying cause. Since the implementation of the varicella vaccination program, varicella-related deaths have declined dramatically to the lowest level ever reported; rates of mortality due to varicella in the United States are now considerably lower than the reported rates in countries that do not have a universal vaccination program.12,13,14,15,16,17 Varicella-related deaths have declined among children and among adults 20 to 49 years of age, and mortality rates are similar for all racial and ethnic groups and for persons born inside the United States and those born in other countries. However, most deaths related to varicella continue to occur among persons who do not have high-risk conditions and who are eligible for vaccination.
Again, costs are often underestimated because the calculations are limited to direct costs of varicella only. The cost of a number of complications did not count.
Additional studies people might want to look at:
Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States.
Impact of varicella vaccination on health care utilization.
Additionally I noticed in
these cost benefit analyses there was the assumption that zoster would increase. Few attempts were made to address decreasing the increase in zoster cases by boosters and calculate the entire cost. So you have to look at whose cost is being looked at when evaluating varicella vaccine, and you need to determine just what is being included in the calculations.
It isn't clear just what an increase in zoster cases in people with healthy immune systems will mean. It could be that those are not the persons who would suffer complications from zoster anyway. After all, you are talking about zoster cases that would have been prevented by natural exposure boosting. One might hypothesize that those would be more likely to be mild uncomplicated cases and zoster occurrences not prevented by natural exposure boosting were more likely to be complicated cases. In any case, I think it is too easy to overlook these multiple variables and erroneously come up with data to support the vaccine not being cost effective.
Regarding the increase in zoster following introduction of vaccine, the Australian public health recommendation had this in their discussion:
The Australian Immunisation Handbook - 3.27 VARICELLA-ZOSTER
Two epidemiological studies from the United Kingdom suggest that exposure to varicella may help prevent herpes zoster, presumably by boosting immunity. 11,12 A study using mathematical modelling and a number of assumptions has predicted that, following the introduction of varicella-zoster vaccination, there could be a short to medium term increase in the incidence of herpes zoster with a shift in the age of cases into younger age groups (because naturally infected persons would have less opportunity to be exposed to varicella). 11,13 However, as the vaccine strain of varicella virus causes herpes zoster significantly less frequently,8 not only varicella but also herpes zoster could ultimately be eliminated. It must also be emphasised that there is no direct proof that herpes zoster epidemiology will be altered by the introduction of varicella-zoster vaccination. Indeed, current surveillance in USA shows no change in herpes zoster incidence after 5 years of routine vaccination. In Australia, South Australia began passive surveillance of varicella and herpes zoster from January, 2002. Other surveillance mechanisms are in place nationally (eg. hospitalisations) to track the varicella and herpes zoster disease burden following the introduction of vaccination programs.
Other studies did not corroborate the failure to see increased zoster but most of the discussions relied on long term modeling projected increases based on short term data sets.
BTW, here's another lesson in how to misunderstand a medical researhc abstract when you don't have a thorough understanding of a disease.
Epidemiology of varicella-zoster virus in England and Wales
Abstract
Many countries are studying currently the possibility of mass vaccination against varicella. The objective of this study was to provide a complete picture of the pre-vaccine epidemiology of the Varicella-Zoster Virus in England and Wales to aid in the design of immunisation programs. Population-based data including general practitioner sentinel surveillance, hospitalisation data, and death certificates from England and Wales were analysed. The average incidence rates for varicella and zoster between 1991 and 2000 were 1,291 and 373 per 100,000 years, respectively. Overall hospitalisation rates were equal for varicella and zoster (4.5 vs. 4.4 hospitalisation per 100,000 population) with 5 and 8%, respectively, having underlying immunosuppressive conditions. The age-specific proportion of cases hospitalised and length of stay were similar between the two diseases. However, the overall burden of disease is considerably higher for zoster. The number of inpatient days and case-fatality due to zoster are roughly 4 to 6 times greater than for varicella (11 vs. 3 days and 25 vs. 4 deaths per 100,000 case). These results provide base-line estimates should mass varicella vaccination be introduced in England and Wales.
The baseline referred to here is intended to be compared to changes over time with implementation of vaccine programs. The conclusion for this abstract is in the italicized text.
There is not a claim here that primary varicella is not as bad as zoster. If you don't understand the disease, the population affected, the expected course of disease, then you are going to grossly misunderstand what the bolded text means. I can't overemphasize this enough. Nothing here says that without natural boosting, zoster is going to hospitalize or kill more people. Nothing here says that without natural boosting zoster will be more dangerous to people with healthy immune systems. This says nothing of the kind. You cannot assess the increased risk of zoster from decreasing primary chicken pox from the bolded data. You have no denominators. And all those people with zoster also had chicken pox initially. The disease process differs between the two presentations of the infection. The average age and additional disease conditions vary between the two groups.
As a medical practitioner, I don't draw the conclusion from this that having natural virus around boosting people against zoster is better than vaccinating people. I can see why the statement is being misunderstood.
I ask the other physicians and practitioners here to give their take on that bolded text and how it is being misunderstood by Ivor. I'm at a loss for words to explain it in 25 words or less.